The Filing Desk

Journey Medical vs Enanta Pharmaceuticals

Journey Medical DERM · Enanta Pharmaceuticals ENTA · Pharmaceuticals

Enanta Pharmaceuticals reported revenue of $63 million in fiscal 2026, about the same as Journey Medical's $62 million in fiscal 2025. Journey Medical's revenue grew 10.2% in its latest year, and Enanta Pharmaceuticals' fell 3.6%. Journey Medical had an operating margin of -13.2%, against -99.0% at Enanta Pharmaceuticals. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.

Side by side

Journey MedicalEnanta Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Sep 30, 2026
Revenue$62M$63M
Revenue growth10.2%−3.6%
Revenue growth a year, last 5 years6.8%−8.3%
Gross margin66.2%—
Operating margin−13.2%−99.0%
Net margin−18.5%−108.3%
Free cash flow—−$43M
Free cash flow margin—−67.9%
Return on capital−22.4%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count19.9%35.9%
Last close$3.55$7.98
P/E at the last close——
Insider trades, last 12 months—sold $183,168
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Journey MedicalEnanta Pharmaceuticals
Operating margin
Percent of revenue
Journey MedicalEnanta Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Journey MedicalEnanta Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Journey Medical and Enanta Pharmaceuticals pages.